With the amount of cases crossing six million (and more than three hundred and seventy thousand deaths) worldwide, there is a dire need of a vaccine (and repurposing of drugs) for SARS-CoV-2 disease (COVID-19). strand RNA virus (a member of the coronavirus family) called SARS-CoV-2 ,  does not, as of now, have any treatment and a majority of its aspects are yet unknown . Initial attempts with repurposing of certain drugs have seen little success. Though previous coronavirus outbreaks can be used to model or understand SARS-CoV-2 and the disease it causes, but it is to be understood that no vaccine offers yet been created for any from the coronaviruses (including SARS-CoV-1 and MERS). While may be the whole case numerous viral illnesses there is absolutely no vaccine for COVID-19. This is regardless of the known fact that arduous efforts are being effectuated globally with this direction . None of the efforts have however prevailed. This paper proposes B-cell genome executive like a coherent strategy to foster the introduction of a highly effective vaccine against SARS-CoV-2 and several other viruses which have evaded the chance of vaccine advancement through conventional strategies. Since vaccines will be the most sought-after treatment for just about any disease presumably. To this impact, a vaccine must elicit a managed immune system response in the receiver without problems and quick the immune strength to persist. Despite years of dedicated efforts, such vaccines designed to offer lifelong safety against many viral real estate agents like respiratory syncytial Fosamprenavir disease (RSV), human being immunodeficiency Fosamprenavir disease (HIV), influenza and Epstein-Barr disease (EBV) never have yet been possible. While many reasons can be attributed to this verity, a genome editing based approach to substitute/replace the endogenously-encoded antibodies with antibodies targeted at specific antigens (various parts of the SARS-CoV-2 in this case) in human B-cells may prove to be an efficient strategy to develop a safe, effective, and long-lasting vaccine. This paper proposes/hypothesizes B-cell genome engineering as a cogent rationale to develop a viable vaccine for SARS-CoV-2. This paper also explicates the stepwise methodology for translating this idea into G-ALPHA-q reality. This paper also discusses the potential technological constraints and deliberates upon the coherent modus operandi to overcome such impediments. Theory In principle, CRISPR/Cas9 mediated genome editing approaches have a potential to edit mammalian cell genomes with extreme precision and this approach is not restricted to correcting the defective parts of the genome. Genomes can be modified and specifically repurposed towards important goals of improved and refined functions. With this premise, it can be hypothesized that a similar approach would be plausible to engineer human B-cells. To this effect, well-orchestrated expression of particular antibodies may be accomplished beneath the control of endogenous regulatory components in charge of antibody creation (manifestation and secretion of regular antibodies) in these cells. The Fosamprenavir essential mechanism by which many vaccines Fosamprenavir function is the creation of antibodies by turned on B-cells. This process appears articulate first but has its handicaps particularly important to RNA infections. Refashioning B-cells through genome-editing technology (like CRISPR/Cas9 mediated gene Fosamprenavir editing) to obtain certain essential properties may take care of this difficulty. In cases like this the B-cells could be aimed at obtaining particular properties like (1) adequate expression of the precise antibody, (2) negligible or no manifestation from the unintended antibody, (3) higher temporal viability from the therefore built B-cell clones in the body and (4) the salience to be relatively harmless and non-oncogenic. A repertoire of such mobile clones will probably solve the issue not merely for the SARS-CoV-2 but also of additional viral pathogens. Vaccines quick B-cells to create antibodies against particular antigens (epitopes) from the pathogen (e.g. S-spike proteins in case there is SARS-CoV-2). B-cells accomplish that destiny by rearrangement from the three essential the different parts of the antibodies within their genomes, the V, J and D regions. Some known reasons for failing of vaccines are that such a gene rearrangement (1) might not effectively happen, (2) could be postponed, (3) may possibly not be long-lasting and (4) may possibly not be able to support an adequate and sufficiently particular response. Another important concern with antibody-based vaccines would be that the antibodies gets depleted within a short period of your time and hence have to be given repeatedly at certain intervals of your time. That is yet another reason to engineer B-cells in a genuine way in order that they continue producing.